Terri Lynn Parker MD

Assistant Professor of Medicine (Hematology); Assistant Professor

Specialties & Subspecialties

Cancer Center, Yale: Hematology Program


Education & Training

  • B.S., University of Pittsburgh (2001)
  • M.D., St. George's University School of Medicine Grenada (2005)
  • Residency, University of Connecticut Health Center , Internal Medicine (2005 - 2008)
  • Fellowship, University of Connecticut Health Center , Hospice and Palliative Med (2008 - 2009)
  • Fellowship, Yale University School of Medicine , Hematology and Medical Oncology (2009 - 2012)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | NA

Clinical Interests

Benign and Malignant Hematology; Hospice and Palliative Medicine

Cancers Treated


Board Certifications

  • Hospice & Palliative Medicine, Board Certified (2010)
  • Hematology (Internal Medicine), Board Certified (2012)
  • Internal Medicine, Board Certified (2008)

Clinical Trials

ConditionsStudy Title
Leukemia, not otherwise specified and Myeloid and Monocytic LeukemiaAn Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Volasertib (BI 6727) in Combination with Decitabine in Patients with Acute Myeloid Leukemia
Leukemia, otherPhase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML
Non-Hodgkin's LymphomaPhase 1 Dose Finding Study of Belinostat plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients with Peripheral T cell Lymphoma (PTCL)

Edit Profile